loading page

Potential Efficacy of Thymosin α1 in the Treatment of Lymphocytopenia and T Cell  Exhaustion Associated with COVID-19
  • Thumbnail
  • Milad Shirvaliloo
Milad Shirvaliloo
Author Profile
Medium

Abstract

It is not unbeknownst to us that since the very onset of the COVID-19 outbreak, many patients from different age groups have suffered greatly, and in a remarkable number of cases, succumbed to their untimely demise as a result of infection with the novel coronavirus or SARS-CoV-2. The elderly are perhaps the most vulnerable group of people, who stand at the pinnacle of morbidity and mortality rates due to contracting severe forms of COVID-19. Hopefully, based on the recent findings and the present evidence, there might be a number of medications that would possibly be of great prophylactic and therapeutic value to the elderly patients diagnosed with COVID-19. According to an interventional study, Thymosin α1 is arguably one such medication that has recently been indicated to be an effective therapeutic agent for inpatient correction of lymphocytopenia and T cell exhaustion caused by COVID-19.